Navigation Links
DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
Date:2/12/2008

RALEIGH, N.C. and WELLESLEY HILLS, Mass., Feb. 12 /PRNewswire/ -- DARA BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ("Point") (Nasdaq: POTP) announced the consummation of their merger transaction, effective as of the close of business on February 12, 2008.

The merger was completed after approval by the respective stockholders of DARA and Point. Immediately prior to the consummation of the merger, Point effected a reverse stock split of its common stock pursuant to which each 40 shares of Point common stock issued and outstanding was converted into one share of Point common stock. As a result of the merger, DARA stockholders will receive 1.031406 shares of Point common stock for each share of DARA common stock and preferred stock held immediately prior to the transaction.

In making the announcement, DARA's Chairman Richard A. Franco, Sr., commented, "We are pleased to have completed this transaction and appreciate the confidence of the stockholders of DARA and Point as evidenced by their votes."

Upon consummation of the merger, DARA became a wholly-owned subsidiary of Point, and Point changed its name to DARA BioSciences, Inc. The combined company's common stock will continue to trade on the NASDAQ Capital Market under the symbol "DARA ". Additionally, the Board of Directors and executive officers of DARA will lead the combined company.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.

As of February 13, 2008, DARA will trade on the NASDAQ Capital Market under the ticker symbol "DARA".

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabiosciences.com.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
3. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
4. Jill Birkett Appointed Event Director for HBA Global Expo
5. USHEALTH Group Announces Appointment of Executive Vice President
6. ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board
7. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
8. AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors
9. Natural Alternatives International, Inc. Appoints New Chief Financial Officer
10. Deerfield Spa Appoints New Fitness Director
11. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... protection assistance and finance management services to communities across North Carolina, is launching ... Advocacy Network to raise community support for the ongoing fight against bladder cancer. ...
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn ... taking advantage of a new benefit for employees that is uncommon in American business: ... the company supports me and other employees as new parents. It keeps our family ...
(Date:7/24/2017)... ... 2017 , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been ... (SLMBNI), part of Saint Luke’s Health System . Dr. Upadhyaya has served in ... M.Sc., FAANS joins Stanley P. Fisher, M.D., who has served as medical ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly Topical ... Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... term skin conditions, including cancer. In the short term, overexposure to sun, ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... RESEARCH TRIANGLE PARK, N.C. , July 10, 2017 ... of a $5m Convertible Note to support the development ... led by Tencent Holdings Limited, a leading Chinese Internet ... Center. This funding will advance multiple infectious disease product ... Founded by Dr. ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
(Date:7/5/2017)... -- Pace Analytical, a company of over 2,000 employees and a leader in ... Lab Sciences, further solidifying their position as the top American owned and operated ... ... Pace Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative ...
Breaking Medicine Technology: